Our people

"What drives me the most is solving difficult problems, in collaboration with others, for the benefit of the patient and the business."

Mark Fielding, Associate Principal Scientist, Global Medicines Development

View Mark's profile

Our people

"There is an expanding universe of biological data available which can revolutionise our understanding of disease and therapy if we find innovative ways to share and explore it."

Jonathan Dry, Principal Scientist, Bioinformatics, Oncology, Innovative Medicines & Early Development

View Jonathan's profile

Our people

"I believe personalised healthcare is the future of medicine; it allows us to use the latest diagnostic science to target medicines to patients most likely to benefit."

Ruth March, Vice-President and Head of Personalised Healthcare and Biomarkers, IMED Biotech Unit

View Ruth's profile

Matthew Thomas

PhD, Head of Department (interim) and Principal Scientist, RIA Bioscience Regeneration

Katerina Pardali

Associate Principal Scientist, IMED Biotech Unit (Respiratory, Inflammation & Autoimmunity)

Roland Kolbeck

PhD, VP, R&D Respiratory, Inflammation and Autoimmunity (RIA)

David Keeling

Project Director, IMED Biotech Unit (Respiratory, Inflammation & Autoimmunity)

Stephen Delaney

Associate Director, IMED Biotech Unit (Respiratory, Inflammation & Autoimmunity)

Benoit Destenaves

Director, Molecular Diagnostics Labs and Pharmacogenomics, IMED Biotech Unit

Mark Fielding

Associate Principal Scientist, Global Medicines Development

Regina Fritsche-Danielson

Senior Director and Head of Bioscience Heart Failure Department, IMED Biotech Unit (Cardiovascular and Metabolic diseases)

Jonathan Dry

Principal Scientist, Bioinformatics, Oncology, Innovative Medicines & Early Development

View Jonathan's profile

Ruth March

Vice-President and Head of Personalised Healthcare and Biomarkers, IMED Biotech Unit

View Ruth's profile

Li-Ming Gan

Medical Science Director, Early Clinical Development (Cardiovascular and Metabolic diseases)

Shaun Grady

Vice-President Business Development Operations

Maria Groves

Associate Director, Head of the CRUK MedImmune Alliance Laboratory (CMAL)

Bahija Jallal

Executive Vice-President, MedImmune

William Dall’Acqua

Senior Director, R&D, Antibody Discovery and Protein Engineering, MedImmune

Biljana Naumovic

Country President, Switzerland

Margareta Ozolins

Vice-President Sweden, Operations

Mark O’Connor

Chief Scientist, IMED Biotech Unit (Oncology)

Jane Osbourn

Vice-President Research and Development, MedImmune

View Jane's profile

Menelas Pangalos

Executive Vice-President, IMED Biotech Unit

View Menelas's profile

Kumar Srinivasan

Vice-President, Scientific Partnering and Alliances and Site Head, R&D Boston

Helen Angell

Associate Principal Scientist, Oncology, Translational Sciences, IMED Biotech Unit

Emma Dean

Director, Early Phase Oncology, Early Clinical Development

Amy Taylor

Associate Director, Strategic Planning and Operations, Early Clinical Development and Chair of the Network of Women UK

Christopher J. Rhodes

VP, Cardiovascular & Metabolic Disease Research, MedImmune

Nicolas Jose Guzman

Director, Nephrology Clinical Research; CVMD US Group Director

David Wilson

Senior Director and Global Head of Oncology Chemistry, IMED Biotech Unit

Anthony Johnson

Vice President, Early Clinical Development, IMED Biotech Unit

Paul Harper

Associate Principal Scientist, Discovery Sciences, IMED Biotech Unit

Craig Wegner

Head, Boston Emerging Innovations Unit, Scientific Partnering & Alliances, AstraZeneca IMED Biotech Unit

Dónal Landers

Senior Director Physician OncTMU Early Clinical Development Clinical Leader – iDecide Programme, CRUK Manchester Institute

Herren Wu

Chief Technology Officer and Global Head of Antibody Discovery and Protein Engineering (ADPE), MedImmune

Our focus areas

Cardiovascular and Metabolic diseases

Oncology

Respiratory

Inflammation and Autoimmunity

Neuroscience

Infection and Vaccines